Trade

with

XOMA Corp
(NASDAQ: XOMA)
AdChoices
4.25
+0.23
+5.59%
After Hours :
4.25
0.00
0.00%

Open

4.03

Previous Close

4.03

Volume (Avg)

853.84k (1.32M)

Day's Range

4.03-4.26

52Wk Range

3.42-9.57

Market Cap.

430.99M

Dividend Rate ( Yield )

-

Beta

2.98

Shares Outstanding

107.08M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 35.45M

    • Net Income

    • -124.06M

    • Market Cap.

    • 430.99M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -348.96

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.98

    • Forward P/E

    • -9.25

    • Price/Sales

    • 14.71

    • Price/Book Value

    • -56.82

    • Price/Cash flow

    • -6.23

      • EBITDA

      • -116.87M

      • Return on Capital %

      • -118.06

      • Return on Equity %

      • -

      • Return on Assets %

      • -118.06

      • Book Value/Share

      • -0.07

      • Shares Outstanding

      • 107.08M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 11.50

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.50

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -16.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -12.21

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -349.01

            • 39.38

            • Net Profit Margin

            • -348.96

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 99.90

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -162.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -164.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 2.22

              • 2.92

              • Quick Ratio

              • 2.16

              • 2.35

              • Interest Coverage

              • -20.74

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.07

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.95

                • 188.68

                • P/E Ratio 5-Year High

                • -12.64

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.04

                • 124.82

                • Price/Sales Ratio

                • 14.39

                • 8.72

                • Price/Book Value

                • -55.87

                • 7.95

                • Price/Cash Flow Ratio

                • -6.23

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -118.06

                        (-66.20)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.34

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -58.20M
                      Operating Margin
                      -164.18
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -6.23
                      Ownership

                      Institutional Ownership

                      78.12%

                      Top 10 Institutions

                      63.11%

                      Mutual Fund Ownership

                      28.45%

                      Float

                      66.34%

                      5% / Insider Ownership

                      1.18%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        4,689,019

                      • 0.00

                      • 4.38

                      • Fidelity® Advisor Small Cap Opps Fund

                      •  

                        2,524,322

                      • 0.00

                      • 2.36

                      • UBS (Lux) EF Biotech (USD)

                      •  

                        1,679,900

                      • 0.00

                      • 1.57

                      • Fidelity Advisor® Growth Opportunities

                      •  

                        1,576,700

                      • 0.00

                      • 1.47

                      • Fidelity® Puritan® Fund

                      •  

                        1,530,200

                      • 0.00

                      • 1.43

                      • Fidelity® OTC Portfolio

                      •  

                        1,521,913

                      • 0.00

                      • 1.42

                      • iShares Nasdaq Biotechnology

                      •  

                        1,431,286

                      • 3.08

                      • 1.28

                      • iShares Russell 2000 (AU)

                      •  

                        1,330,517

                      • -1.01

                      • 1.19

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,234,184

                      • 0.00

                      • 1.15

                      • Vanguard Extended Market Index Fund

                      •  

                        827,511

                      • 0.54

                      • 0.77

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Baker Bros Advisors LLC

                      •  

                        23,065,972

                      • +0.04%

                      • 21.55

                      • Fidelity Management and Research Company

                      •  

                        15,906,009

                      • +0.29%

                      • 14.86

                      • Eastern Capital LTD

                      •  

                        7,985,790

                      • +26.82%

                      • 7.58

                      • Deerfield Management Co

                      •  

                        3,806,868

                      • -38.11%

                      • 3.61

                      • Kingdon Capital Management LLC

                      •  

                        3,548,313

                      • +4.46%

                      • 3.31

                      • BlackRock Fund Advisors

                      •  

                        3,347,899

                      • -2.59%

                      • 3.13

                      • Vanguard Group, Inc.

                      •  

                        3,079,289

                      • +28.03%

                      • 2.88

                      • Orbimed Advisors, LLC

                      •  

                        2,437,000

                      • 0.00%

                      • 2.28

                      • Driehaus Capital Management LLC

                      •  

                        2,314,541

                      • -15.54%

                      • 2.16

                      • UBS Global Asset Management Zurich

                      •  

                        1,871,400

                      • 0.00%

                      • 1.75

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      XOMA Corp was incorporated in Delaware on 1981 and became a Bermuda-exempted company in December 1998. The Company is a biotechnology company, which is engaged in the discovery, development and manufacture of therapeutic antibodies a...morend other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company builds a product pipeline that includes multiple proprietary and collaborative development programs. Its proprietary preclinical pipeline includes classes of antibodies that activate, sensitize, or deactivate the insulin receptor in vivo, that have been named as XMet. This portfolio of antibodies represents potential new therapeutic approaches to the treatment of diabetes and several diseases that involve insulin, which it believe may be orphan drug opportunities....more Its main product candidate is XOMA 052, a potent monoclonal antibody with the potential to improve the treatment of patients with a number of diseases in which inflammation is either the cause or plays a considerable role. The company receives royalties on approved products, RAPTIVA®, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis, LUCENTIS®, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration, and the Company no longer receives royalties on sales of CIMZIA®. XOMA has granted more than 60 licenses to biotechnology and pharmaceutical companies to use the Company’s patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products.lessless

                      Key People

                      John Varian

                      CEO/Director

                      W. Denman Van Ness

                      Chairman of the Board/Director

                      Dr. Patrick J. Scannon,M.D.,PhD

                      Chief Scientific Officer/Director/Executive VP/Founder

                      Fred Kurland

                      CFO/Secretary/Vice President, Divisional

                      Mr. Thomas Klein

                      Other Executive Officer/Vice President

                      • XOMA Corp

                      • 2910 Seventh Street

                      • Berkeley, CA 94710

                      • USA.Map

                      • Phone: +1 510 204-7200

                      • Fax: -

                      • xoma.com

                      Incorporated

                      1981

                      Employees

                      180

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: